Clinical Trial Update: A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression [Phase 2]

View source ↗

Summary

A Phase 2, single-arm exploratory trial evaluating a triple combination of anlotinib, TQB2450, and the SOX chemotherapy regimen as first-line therapy for advanc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• OXALIPLATIN (Oxaliplatin)
• S-1 (tegafur/gimeracil/oteracil)
• TQB2450

Snippet

Sponsor: Yongxu Jia | Conditions: Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING